Home / Business and Economy / Nestle Turns Weight-Loss Drug Threat into Product Opportunity
Nestle Turns Weight-Loss Drug Threat into Product Opportunity
17 Aug
Summary
- Nestle uses AI and nutritional science to create products for GLP-1 drug users.
- Products aim to address side effects like muscle loss and 'Ozempic face'.
- AI helps analyze research, develop new recipes, and simulate consumer behavior.
Nestle is strategically pivoting to address the growing market of consumers using GLP-1 weight-loss drugs. The company is harnessing artificial intelligence and advanced nutritional science to create a new line of products designed to combat the side effects associated with rapid weight loss, such as muscle mass reduction and changes in facial appearance. This initiative aims to turn a potential threat to its core business into a significant opportunity.
Utilizing AI, Nestle is analyzing extensive clinical research to identify optimal nutrient combinations and develop innovative solutions. Their efforts include fortifying products with collagen protein to support skin and hair health and developing micronutrient blends to stimulate muscle tissue growth. Nestle has also patented ingredient combinations to help manage increased hunger experienced by some users after discontinuing GLP-1 treatments.
The company has already introduced tailored products, including the Boost Advanced Nutrition Shake in the U.S. and a high-protein version of Milo in Asia and Australia. Internally, Nestle employs AI platforms like Food Genie to analyze vast recipe databases, predict product performance, and identify formulation opportunities, alongside simulating consumer behavior to anticipate market reception before product launches.
